Welcome to our dedicated page for Senti Biosciences news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Biosciences stock.
Senti Biosciences, Inc. (Nasdaq: SNTI) is a pioneering biotechnology company focused on developing next-generation cell and gene therapies. The company leverages its proprietary Gene Circuit platform to engineer adaptive therapies for treating complex diseases, with a strong focus on oncology. Senti Bio's core technology harnesses synthetic biology to create precision gene circuits that can enhance the efficacy and safety of cellular therapeutics.
Founded by a team of engineers, scientists, and entrepreneurs, Senti Biosciences has rapidly advanced its research and development through strategic partnerships and significant investments. The company's innovative approach utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells integrated with gene circuits to address challenging diseases. Senti Bio’s primary product candidates include SENTI-202 for hematologic malignancies like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), and SENTI-301A for the treatment of hepatocellular carcinoma (HCC).
- SENTI-202 employs Logic Gated CAR-NK cells designed to selectively target and eliminate cancer cells expressing CD33 and/or FLT3 antigens while sparing healthy bone marrow cells. The company received clearance from the U.S. FDA for its Investigational New Drug (IND) application and plans to initiate a Phase 1 clinical trial in 2024.
- SENTI-301A is designed for the treatment of HCC and is currently being developed in collaboration with Celest Therapeutics in China.
In addition to its primary pipeline, Senti Bio is actively exploring the potential of its Gene Circuit technology in other therapeutic areas and modalities, including partnerships with Spark Therapeutics and BlueRock Therapeutics. The company is committed to advancing its clinical programs and demonstrating the transformative potential of Gene Circuits in precision medicine.
Recent achievements include the establishment of a manufacturing partnership with GeneFab to support clinical-scale production and streamline operations to focus on key clinical programs. Senti Bio’s financial results reflect ongoing investments in research and development, with strategic efforts aimed at extending its cash runway and ensuring the successful advancement of its therapeutic candidates.
Senti Biosciences stays at the forefront of biotechnology innovation, dedicated to developing superior treatments for patients facing incurable diseases. Stay updated with Senti Bio’s latest developments and progress through their website and social media channels.
Senti Biosciences announced at the ASH Annual Meeting progress on SENTI-202, an off-the-shelf CAR-NK cell therapy, showcasing preclinical data indicating effective targeting of CD33 and FLT3 expressing tumors, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The candidate is on track for an IND filing in 2H 2023. The data demonstrates significant cancer-killing activity in vitro and in vivo, while protecting healthy cells. This development highlights the potential for SENTI-202 to revolutionize treatment for patients with these hematologic malignancies.
Senti Biosciences, Inc. (Nasdaq: SNTI) will host an Investor Event on December 11, 2022, from 11:30 a.m. to 12:30 p.m. CST during the 64th ASH Annual Meeting in New Orleans, LA. The event will cover preclinical data and clinical plans for SENTI-202 aimed at treating hematologic malignancies like AML. Notable speaker Stephen A. Strickland, Jr., MD, will discuss the treatment landscape. Attendance is available in-person and virtually, with a webcast accessible on Senti's Events page.
The meeting is independent from the official ASH program.
Senti Biosciences reported progress in its clinical pipeline with SENTI-202 and SENTI-301A targeting hematologic and solid tumors, respectively. The company expects to file IND applications for both candidates in 2023. As of September 30, 2022, Senti Bio had $114.9 million in cash, projected to sustain operations into 2024. The third-quarter net loss was $16.6 million, or $0.38 per share, with increased R&D and G&A expenses. Notably, the company highlighted promising preclinical data at the SITC Annual Meeting, reinforcing its innovative gene circuit technology.
Senti Biosciences (Nasdaq: SNTI) announced a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting showcasing preclinical data for SENTI-202, a CAR-NK cell therapy targeting CD33 and FLT3 in acute myeloid leukemia (AML).
The presentation is scheduled for December 10, 2022, from 5:30 - 7:30 pm CST, at the Ernest N. Morial Convention Center, New Orleans. The therapy employs Logic Gating gene circuit technology to enhance targeting efficacy while protecting healthy cells. More details will be available post-presentation on Senti Bio's website.
Senti Biosciences (SNTI) announced the granting of stock options for 200,200 shares to nine new employees, priced at $2.39 per share. This decision, finalized on October 27, 2022, was made in accordance with NASDAQ rules and as part of the newly adopted 2022 Inducement Equity Plan. The company is focused on developing advanced cell and gene therapies using its proprietary Gene Circuit platform to enhance treatment for various complex diseases, particularly in oncology.
Senti Bio announced two upcoming poster presentations at the Society for Immunotherapy of Cancer's 37th Annual Meeting, scheduled for November 10-12, 2022, in Boston. The presentations will focus on gene circuits to enhance CAR-NK cell therapy for treating solid tumors. Key topics include SENTI-401, which targets CEACAM5-expressing cancers, enhancing selectivity and efficacy. The event aims to showcase Senti Bio's innovative approach using its proprietary gene circuit platform to tackle significant oncology challenges.
Senti Biosciences, Inc. (Nasdaq: SNTI) announced participation by co-founder and CEO Tim Lu, CFO Deb Knobelman, and CMDO Kanya Rajangam in a Fireside Chat at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022. Tim Lu will also join a panel on Gene Regulation on October 4, 2022. Live webcasts of the events will be available on Senti Bio's website for 120 days following the presentations. Senti Bio aims to develop innovative cell and gene therapies through its proprietary Gene Circuit platform.
Senti Biosciences, Inc. (Nasdaq: SNTI) announced participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 4:05 p.m. ET. Co-founder and CEO Tim Lu, CFO Deb Knobelman, and CMDO Kanya Rajangam will engage in a Fireside Chat during the event. A live webcast will be available on the Senti Bio Investors website for 180 days post-presentation. Senti Bio focuses on next-generation cell and gene therapies using their proprietary gene circuit platform to enhance treatment effectiveness for various diseases, including acute myeloid leukemia.
Chardan, a global investment bank, has launched its Chardan Equity Facility (ChEF), a new financing solution for public companies. The ChEF allows firms to raise equity periodically, bypassing traditional follow-on offerings. Senti Biosciences (SNTI) has secured a $50 million ChEF, while Dragonfly Energy (CNTQ) has announced a $150 million agreement. Chardan has raised over $30 billion for companies since its inception, including $10 billion for healthcare sectors, positioning itself as a vital partner for capital access in a challenging market.
Senti Biosciences (Nasdaq: SNTI) announced on August 19, 2022, that its compensation committee granted stock options to 35 new employees, totaling 421,659 shares at an exercise price of $1.99 each. This initiative is part of the Company's 2022 Inducement Equity Plan, adopted on August 5, 2022, to attract and retain talent. Senti Bio is focused on innovative cell and gene therapies using a proprietary gene circuit platform, particularly targeting oncology with several programs in development, including treatments for acute myeloid leukemia and hepatocellular carcinoma.
FAQ
What is the current stock price of Senti Biosciences (SNTI)?
What is the market cap of Senti Biosciences (SNTI)?
What is Senti Biosciences, Inc.?
What are Gene Circuits?
What are Senti Bio's main product candidates?
What is SENTI-202?
What is the status of SENTI-202?
Who are Senti Bio's partners?
What is the focus of SENTI-301A?
How is Senti Bio advancing its manufacturing capabilities?
Where can I find the latest news about Senti Biosciences?
What recent milestones has Senti Bio achieved?
